Ken Griffin Iterum Therapeutics PLC Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.19 - $0.36 $9,597 - $18,185	-50,515 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.31 - $0.45 $8,718 - $12,656	28,125 Added 125.61%	50,515 $18,000
Q4 2021 Feb 14, 2022	BUY	$0.39 - $0.74 $8,732 - $16,568	22,390 New	22,390 $8,000
Q3 2021 Nov 15, 2021	SELL	$0.54 - $2.29 $37,451 - $158,820	-69,354 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$0.97 - $2.39 $65,641 - $161,736	-67,672 Reduced 49.39%	69,354 $160,000
Q1 2021 May 17, 2021	SELL	$0.97 - $2.73 $22,608 - $63,630	-23,308 Reduced 14.54%	137,026 $193,000
Q4 2020 Feb 16, 2021	BUY	$0.46 - $1.2 $68,530 - $178,776	148,980 Added 1312.14%	160,334 $159,000
Q3 2020 Nov 16, 2020	BUY	$0.58 - $1.22 $6,585 - $13,851	11,354 New	11,354 $12,000

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $15.9M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.